Plastic Surgery Industry Stocks( $NBIX, $ALKS, $NEPT...) Post Strong Weekly Gains, Average Increase of 9.38%💰
In the world of biopharmaceutical companies specializing in surgeries and treatments for diseases like solid tumors, cancers, and hematologic malignancies, a select group of stocks has been making waves. These companies not only perform critical surgeries but also provide essential inputs such as sterile biological implants. Among the notable stocks in this theme are Aravive, Neurocrine Biosciences, and RTI Surgical Holdings.
🌐Tickers in Industry - $NBIX, $ALKS, $NEPT, $CYCCP, $EVGN, $SIEN, $ZBH, $SYRS, $ARAV
Market Cap
The average market capitalization across the plastic surgery theme stands at a substantial $4.6 billion. However, within this theme, there's a wide range of valuations, with individual tickers ranging from $220.4 thousand to a whopping $22.1 billion. Zimmer Biomet Holdings (ZBH) holds the distinction of being the highest-valued company in this group, while SRGAQ is at the other end of the spectrum with a valuation of $220.4 thousand.
High and Low Price Notable News
In the last week, stocks within the plastic surgery theme exhibited significant price movement. On average, the weekly price growth for these stocks was an impressive 9.36%. This strong performance is in stark contrast to the average monthly price growth, which recorded a decline of -8.15%, and the average quarterly price growth, which experienced a substantial drop of -30.27%.
CYCCP was the standout performer, experiencing the highest price growth at 50.77%. In contrast, SYRS faced the biggest decline in stock price, falling by -7.8%. It's essential to note that the plastic surgery theme appears to be more resilient on a shorter-term basis, as evidenced by the strong weekly performance.
Volume
The average weekly volume growth across all stocks in the plastic surgery theme saw a decrease of -9.53%. For the same set of stocks within the theme, the average monthly volume growth declined even further, with a significant drop of -42.5%. However, the average quarterly volume growth bucked this trend, recording a healthy increase of 39.34%.
Notably, some individual stocks experienced remarkable volume spikes on specific days. For instance, Sientra (SIEN) saw its volume surge over two consecutive days, resulting in a record-breaking daily growth of 185% of the 65-Day Volume Moving Average. Aravive also had a remarkable day, with its volume surging and achieving a record-breaking daily growth of 386% of the 65-Day Volume Moving Average. Neptune Wellness Solutions also stood out with an astonishing one-day increase of 4,646% of the 65-Day Volume Moving Average.
Fundamental Analysis Ratings
While the provided data doesn't include fundamental analysis ratings, it is worth mentioning that in the world of biopharmaceutical companies specializing in surgeries and treatments, fundamental analysis plays a crucial role in evaluating their long-term prospects. Investors interested in these stocks should consider conducting a thorough fundamental analysis to gauge factors such as revenue, earnings, competitive positioning, and growth potential.
The plastic surgery industry stocks have shown remarkable strength in the last week, with an average gain of 9.38%. Despite some challenges in longer-term price and volume trends, the theme remains an area of interest for investors, with individual stocks exhibiting noteworthy performance. As always, it's essential for investors to conduct their due diligence and consider both technical and fundamental factors when evaluating potential investments in this dynamic sector.
NBIX : NBIX is on the rise, with its 10-day Moving Average crossing above the 50-day moving average on November 13, 2023. This bullish crossover signals an upward shift in the trend, potentially making it an opportune time to consider buying. Historical data reveals that in 11 out of 12 similar instances in the past, when the 10-day surpassed the 50-day, the stock continued its ascent over the subsequent month. With a strong track record, there's a 90% chance of the upward trend persisting, presenting an encouraging outlook for NBIX.
ALKS : ALKS has shown a promising development as its RSI Oscillator broke out of oversold territory on October 26, 2023. This shift suggests a potential transition from a bearish trend to a bullish one, making it an intriguing opportunity for traders. Considering historical data, the A.I.dvisor analyzed 25 comparable instances where the indicator exited oversold territory, revealing that in 22 of those cases, the stock experienced upward movement. This compelling track record implies an 88% probability of a continued uptrend, offering traders a favorable outlook for ALKS. Investors may consider taking positions in the stock or call options to capitalize on this potential upswing.
NEPT : NEPT has registered a positive turn in its Moving Average Convergence Divergence (MACD) Histogram, effective October 11, 2023. This pivotal shift often indicates a potential upward trajectory for the stock. A historical analysis reveals that in 39 out of 46 instances when NEPT's MACD turned positive, the stock continued its ascent over the subsequent month. With an 85% probability of a sustained upward trend, investors should take note of this promising signal and consider their investment strategy accordingly. NEPT may present an appealing opportunity for those seeking to capitalize on the potential price appreciation in the coming weeks.
NBIX in downward trend: price may decline as a result of having broken its higher Bollinger Band on December 16, 2024
NBIX broke above its upper Bollinger Band on December 16, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In of the 40 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for NBIX moved out of overbought territory on December 19, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where NBIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on December 16, 2024. You may want to consider a long position or call options on NBIX as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on December 16, 2024. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
NBIX moved above its 50-day moving average on November 19, 2024 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 263 cases where NBIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.297) is normal, around the industry mean (57.958). P/E Ratio (57.202) is within average values for comparable stocks, (89.727). Projected Growth (PEG Ratio) (0.464) is also within normal values, averaging (2.947). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (19.472).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a product based biopharmaceutical company
Industry PharmaceuticalsOther